UBS’s Heron Therapeutics HRTX Stock Holding History

UBS’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-1,300	Closed	-$16K	–	10519
2014 Q2	$16K	Sell	1,300 -50,876	-98%	-$608K	﹤0.01%	8352
2014 Q1	$726K	Buy	+52,176	New	+$697K	﹤0.01%	3839

Other funds holding HRTX

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

UBS's HRTX Position: Q3 2014 in Review

UBS sold out of Heron Therapeutics (HRTX) in Q3 2014, closing a stake of 1,300 shares — an estimated $16K sold.

UBS first reported a position in HRTX in Q1 2014 and held it in 2 quarters. The position peaked at $726K in Q1 2014. 59 funds tracked by Wall St. Rank hold HRTX as of Q3 2014.

UBS reported no remaining Heron Therapeutics position as of Q3 2014 after selling out during the quarter.
UBS sold 1,300 Heron Therapeutics shares in Q3 2014, an estimated $16K.
UBS first reported a position in Heron Therapeutics in Q1 2014 and held it in 2 quarters.
UBS's Heron Therapeutics position peaked at $726K in Q1 2014.
59 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.